Search for: "Beecham v. Beecham" Results 281 - 300 of 434
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
14 Jul 2010, 7:53 am by Peter S. Lubin and Vincent L. DiTommaso
And it noted that federal courts have previously resolved conflicts between FDA labeling requirements and intellectual property law, including in SmithKline Beecham Consumer Healthcare, L.P. v. [read post]
17 Apr 2014, 9:28 pm by Lyle Denniston
The case of SmithKline Beecham Corp. v. [read post]
17 Oct 2011, 11:56 am
The judge, Justice Bennett, considered the application utilising the principles laid down by Gummow and Hayne JJ in Australian Broadcasting Corporation v O’Neill (2006) 227 CLR 57 at [65], quoting Beecham Group Ltd v Bristol Laboratories Pty Ltd (1968) 118 CLR 618 at 622-623 (per Kitto, Taylor, Menzies and Owen JJ), and accordingly asked whether the plaintiff had: (1) made out a prima facie case; and (2) addressed where the balance of convenience lay? [read post]
19 Apr 2018, 11:37 pm
Now, as  we finally have the decision itself (Decision nr NCL 001, of the 16th of March 2018), there are a number of interesting points to discuss.Background of the caseOn 12 October 2009, Smith Kline Beecham Limited ( “GSK” ) filed a Community plantvariety right (CPVR) application No 2009/1980 for the variety ‘Ben Starav’ of the species Ribes nigrum L.. [read post]
9 Mar 2020, 3:19 pm by Dennis Crouch
” Synthon BV v SmithKline Beecham plc [2006] RPC 10 (Lord Hoffman). [read post]
8 Mar 2011, 1:23 pm by Jason Rantanen
Cir. 2006) (en banc in part) SmithKline Beecham Corp. v. [read post]
13 Sep 2010, 7:50 am
 The same good Lord had a number of cameo roles in IP case; in one, he concurred with Lord Hoffmann in the celebrated House of Lords ruling in Synthon BV v SmithKline Beecham [2005] UKHL 59 (noted here by the IPKat), the paroxetine patent case which turned on issues of enabling disclosure. [read post]